secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001628280-25-008163
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.
- Net loss for Q4 2024 was $104.6 million ($0.76 per share) vs $116.0 million ($0.86 per share) in Q4 2023.
- Phase 3 ECLIPSE registrational program in chronic hepatitis delta on track for first patient in first half of 2025.
- Initial Phase 1 data for VIR-5818 showed tumor shrinkage in 50% (10/20) of participants at doses ≥400 µg/kg.
- Company plans to initiate Phase 1 study of VIR-5525, dual-masked EGFR-targeting T-cell engager, in first half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025008163/0001628280-25-008163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025008163/vir-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer